NAMS
NewAmsterdam Pharma Company N.V.
There isn't enough reported data to score NAMS yet.
NVO
Novo Nordisk A/S
NVO's fundamentals are mixed: it turned 15% of its revenue into free cash flow, but its operating margin fell 3 points to 43%. Its PE isn't a useful guide right now because of how its recent earnings were reported.
NAMS Fundamentals
| Metric | Status |
|---|---|
| Under pressure | |
| Weak | |
| Weak | |
| Strong |
NAMS's balance sheet is currently strong, but its revenue, profitability and cash flow are under pressure.
NVO Fundamentals
| Metric | Status |
|---|---|
| Healthy | |
| Strong | |
| Stable | |
| Healthy |
NVO's revenue, profitability and balance sheet are currently healthy, and its cash flow is stable.
NAMS PE Valuation
NAMS has no meaningful PE right now: it lost money over the past year.
NVO PE Valuation
| Level | PE | Price | Vs current |
|---|---|---|---|
| Current | 10x | $40.65 | — |
| Cheap | 14x | $53.56 | +32% |
| Fair | 27x | $103 | +154% |
| Expensive | 39x | $152 | +273% |
Historical ranges are pointers, not guarantees.
NVO's PE is 10x, but its earnings don't support one, so it isn't a reliable read right now.
NAMS Forward outlook
| Metric | Outlook |
|---|---|
| -- | |
| Losses growing | |
| Strong growth | |
| -- | |
| Limited | |
| Low |
Analysts expect NAMS's losses to grow, with revenue growing. However, they disagree widely on these estimates.
NVO Forward outlook
| Metric | Outlook |
|---|---|
| -- | |
| Stable | |
| Growth | |
| Weakening | |
| Limited | |
| Low |
Analysts expect NVO's revenue to grow, but its profitability to weaken. However, they disagree widely on these estimates.
NAMS Earnings Per Share
| Quarter | TTM EPS | YoY |
|---|---|---|
| Q3 2026 | -$1.68 | +$0.33 |
| Q2 2026 | -$2.15 | -$0.57 |
| Q1 2026 | -$1.78 | +$0.06 |
| Q4 2025 | -$1.72 | +$0.84 |
| Q3 2025 | -$2.01 | +$0.16 |
| Q2 2025 | -$1.58 | +$0.97 |
| Q1 2025 | -$1.84 | +$0.73 |
| Q4 2024 | -$2.56 | -$0.58 |
NAMS is still losing money, but far less than before: $1.68 per share over the past year, against $3.66 at its worst in late 2023.
NVO Earnings Per Share
| Quarter | TTM EPS | YoY |
|---|---|---|
| Q2 2026 | $3.89 | +4.9% |
| Q1 2026 | $4.07 | +17% |
| Q4 2025 | $3.42 | +1.8% |
| Q3 2025 | $3.47 | +10% |
| Q2 2025 | $3.71 | +24% |
| Q1 2025 | $3.49 | +18% |
| Q4 2024 | $3.36 | +21% |
| Q3 2024 | $3.15 | +27% |
NVO has the edge over NAMS on earnings quality, reporting a profit while its opponent remains loss making.
NAMS Quarterly Revenue
| Quarter | Revenue | YoY |
|---|---|---|
| Q3 2026 | $19.2M | +5407% |
| Q2 2026 | $3.7M | -81% |
| Q1 2026 | $3M | +2.1% |
| Q4 2025 | $32K | -100% |
| Q3 2025 | $348K | -99% |
| Q2 2025 | $19.1M | +740% |
| Q1 2025 | $3M | +113% |
| Q4 2024 | $12.8M | +1491% |
NAMS's revenue is recovering but still below its 2022 peak: $19M last quarter, up 5407% from the same quarter a year ago.
| Quarter | Margin | YoY |
|---|---|---|
| Q3 2026 | -231% | +15615 points |
| Q2 2026 | -1753% | -1567 points |
| Q1 2026 | -1922% | +393 points |
| Q4 2025 | -206188% | -205849 points |
| Q3 2025 | -15846% | -15760 points |
| Q2 2025 | -186% | +2121 points |
| Q1 2025 | -2314% | +1646 points |
| Q4 2024 | -338% | +6022 points |
NAMS's operating margin was −231% last quarter, up 15615 points from the same quarter a year ago.
NVO Quarterly Revenue
| Quarter | Revenue | YoY |
|---|---|---|
| Q2 2026 | $11.7B | +2.1% |
| Q1 2026 | $14.4B | +24% |
| Q4 2025 | $11.8B | -7.6% |
| Q3 2025 | $11.1B | +5.1% |
| Q2 2025 | $11.4B | +13% |
| Q1 2025 | $11.6B | +19% |
| Q4 2024 | $12.7B | +30% |
| Q3 2024 | $10.6B | +21% |
NVO's revenue is growing: $11.7B last quarter, up 2.1% from the same quarter a year ago.
| Quarter | Margin | YoY |
|---|---|---|
| Q2 2026 | 34% | -9 points |
| Q1 2026 | 62% | +12 points |
| Q4 2025 | 40% | -2.8 points |
| Q3 2025 | 32% | -16 points |
| Q2 2025 | 44% | +5.4 points |
| Q1 2025 | 50% | +1 points |
| Q4 2024 | 43% | +2.2 points |
| Q3 2024 | 47% | +1.6 points |
NVO has the edge over NAMS on profitability, with a higher operating margin.
NAMS Free Cash Flow
| Quarter | Free cash flow | YoY |
|---|---|---|
| Q3 2026 | -$40M | -$7.1M |
| Q2 2026 | -$39.3M | -$1.5M |
| Q1 2026 | -$30.6M | +$5.8M |
| Q4 2025 | -$41M | -$3.5M |
| Q3 2025 | -$32.8M | -$20.2M |
| Q2 2025 | -$37.8M | +$16.4M |
| Q1 2025 | -$36.5M | +$18.5M |
| Q4 2024 | -$37.5M | -$4.4M |
NAMS has burned cash in almost every quarter: −$151M over the past year, against −$145M the year before.
NVO Free Cash Flow
| Quarter | Free cash flow | YoY |
|---|---|---|
| Q2 2026 | $6.3B | +73% |
| Q1 2026 | $1.8B | +20% |
| Q4 2025 | -$5.4B | -$4.7B |
| Q3 2025 | $4.6B | -2.1% |
| Q2 2025 | $3.6B | -34% |
| Q1 2025 | $1.5B | +89% |
| Q4 2024 | -$632.6M | +$390.5M |
| Q3 2024 | $4.7B | +3.3% |
NVO has the edge over NAMS on cash generation, producing positive trailing cash flow while its opponent burns cash.
NAMS Total Shares
| Period | Change % | Net change |
|---|---|---|
| Quarterly | +0.6% | +766K shares |
| 1 year | +4.3% | +5.1M shares |
| 3 years | +51% | +41.7M shares |
| 5 years | +44% | +38M shares |
NAMS has 124M diluted shares, up 4.3% from a year ago.
| Quarter | Spent |
|---|---|
| Q4 2023 | — |
| Q3 2023 | — |
| Q2 2023 | — |
| Q1 2023 | — |
| Q4 2022 | — |
| Q3 2022 | — |
| Q2 2022 | — |
| Q1 2022 | — |
NVO Total Shares
| Period | Change % | Net change |
|---|---|---|
| Quarterly | -0.3% | -12.9M shares |
| 1 year | -0.2% | -11M shares |
| 3 years | -1.5% | -66.8M shares |
| 5 years | -3.8% | -177M shares |
| Available history | -6.5% | -311M shares |
NVO has the edge over NAMS on shareholder dilution, with a more favorable share count trend.
| Quarter | Spent |
|---|---|
| Q2 2026 | $520M |
| Q1 2026 | $356.7M |
| Q4 2025 | — |
| Q3 2025 | — |
| Q2 2025 | — |
| Q1 2025 | $206.3M |
| Q4 2024 | $1.1B |
| Q3 2024 | $357.4M |
NVO spent $877M buying back its own shares over the past year, down 48% from the year before.
NAMS Net Leverage
| Quarter | Net Leverage | Status |
|---|---|---|
| Q3 2022 | -55.9x | Net Cash |
| Q2 2022 | -2.7x | Net Cash |
| Q1 2022 | -16.5x | Net Cash |
NAMS has more cash than debt.
NVO Net Leverage
| Quarter | Net Leverage | Status |
|---|---|---|
| Q2 2026 | 0.5x | Very low |
| Q1 2026 | 0.7x | Very low |
| Q4 2025 | 0.6x | Very low |
| Q3 2025 | 0.4x | Very low |
| Q2 2025 | 0.5x | Very low |
| Q1 2025 | 0.5x | Very low |
| Q4 2024 | 0.6x | Very low |
| Q3 2024 | -0.0x | Very low |
NVO's net debt is less than a year of its operating earnings (EBITDA).
NAMS Weekly Momentum
| Metric | Value | Status |
|---|---|---|
| RSI | 34.1 | Neutral |
| Stochastic | 10.1 | Oversold |
NAMS's weekly RSI is 34 (neutral) and its Stochastic is 10 (oversold).
NVO Weekly Momentum
| Metric | Value | Status |
|---|---|---|
| RSI | 43.0 | Neutral |
| Stochastic | 27.0 | Neutral |
NVO's weekly RSI is 43 (neutral) and its Stochastic is 27 (neutral).
NAMS PE vs Healthcare Sector
| Metric | NAMS | Sector median | Relative |
|---|---|---|---|
| PE | N/A | 26x | — |
NAMS has no meaningful PE right now: it lost money over the past year.
NVO PE vs Healthcare Sector
| Metric | NVO | Sector median | Relative |
|---|---|---|---|
| PE | 10x | 26x | 60% below |
| PE % | 6 | 29 | 23 pts below |
NVO is trading at 10x earnings, a 60% discount to the Healthcare sector's median of 26x, though its earnings don't support one.
NAMS Weekly Moving Averages
| Moving average | MA price | Relative |
|---|---|---|
| 8 week MA | $20.7 | 3.7% below |
| 20 week MA | $25.2 | 21% below |
| 50 week MA | $30.0 | 33% below |
| 100 week MA | $27.3 | 27% below |
| 200 week MA | $21.4 | 6.6% below |
NAMS is in a downtrend: it's below all five of its weekly moving averages, and 6.6% below its 200-week average.
NVO Weekly Moving Averages
| Moving average | MA price | Relative |
|---|---|---|
| 8 week MA | $39.2 | 3.7% above |
| 20 week MA | $43.9 | 7.4% below |
| 50 week MA | $45.3 | 10% below |
| 100 week MA | $56.3 | 28% below |
| 200 week MA | $80.7 | 50% below |
NVO has the edge over NAMS on trend strength, trading above more of its moving averages.
NAMS Yearly ROI
| Year | Start price | End price | ROI |
|---|---|---|---|
| 2021 | $10.6 | $9.74 | -8.5% |
| 2022 | $9.74 | $11.3 | +16% |
| 2023 | $11.3 | $11.2 | -1.2% |
| 2024 | $11.2 | $25.9 | +132% |
| 2025 | $25.9 | $35.3 | +36% |
| 2026 YTD | $35.3 | $20.0 | -43% |
NAMS is down 43% so far in 2026, after finishing higher in three of the previous five years.
NVO Yearly ROI
| Year | Start price | End price | ROI |
|---|---|---|---|
| 2020 | $29.1 | $34.7 | +19% |
| 2021 | $34.7 | $54.2 | +56% |
| 2022 | $54.2 | $67.0 | +24% |
| 2023 | $67.0 | $103.5 | +54% |
| 2024 | $103.5 | $87.4 | -16% |
| 2025 | $87.4 | $52.4 | -40% |
| 2026 YTD | $52.4 | $40.7 | -22% |
NVO has the edge over NAMS on returns for 2026, with the stronger performance.